Development of treatment strategies for advanced HER2-positive gastric cancer: Insights from clinical trials.

 0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Yuansong Bai, Jing Cai, Dan Cong, Wanning Wang, Wenlong Zhang

Ngôn ngữ: eng

Ký hiệu phân loại: 965.054 1992-

Thông tin xuất bản: Netherlands : Critical reviews in oncology/hematology , 2025

Mô tả vật lý:

Bộ sưu tập: NCBI

ID: 641590

HER2-positive gastric cancer (GC), a unique molecular subtype, has garnered significant interest in recent years. Here, we review clinical trial data on advanced HER2-positive GC from the past 15 years. Trastuzumab plus standard chemotherapy remain the first-line treatment. The initial survival benefits conferred by immune checkpoint inhibitors plus trastuzumab and standard chemotherapy are encouraging. The combination of ramucirumab and mono-chemotherapy, as well as the antibody conjugated drug trastuzumab deruxtecan, is the recommended second-line regimen. Treatment with immune checkpoint inhibitors plus ramucirumab and mono-chemotherapy shows promise. Despite the limited treatment options for third line and beyond, development of novel therapeutic strategies is expected. Although clinical cure of advanced HER2-positive GC is unlikely, current clinical studies offer valuable insight into regimens that prolong survival.
Tạo bộ sưu tập với mã QR

THƯ VIỆN - TRƯỜNG ĐẠI HỌC CÔNG NGHỆ TP.HCM

ĐT: (028) 36225755 | Email: tt.thuvien@hutech.edu.vn

Copyright @2024 THƯ VIỆN HUTECH